27.56

2.87% 0.77

After Hours: 27.56

Travere Therapeutics Inc (TVTX)

Overview News Price History Option Chain Financials Why TVTX Down? Discussions Forecast Stock Split

Travere Therapeutics Inc stock is traded at $27.56, with a volume of 1.57M. It is up +2.87% in the last 24 hours and down -6.07% over the past month. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Previous Close:

$26.79

Open:

$26.84

24h Volume:

1.57M

Relative Volume:

0.79

Market Cap:

$2.54B

Revenue:

$490.73M

Net Income/Loss:

$-50.26M

P/E Ratio:

-45.70

EPS:

-0.603

Net Cash Flow:

$-20.37M

1W Performance:

+2.23%

1M Performance:

-6.07%

6M Performance:

+12.01%

1Y Performance:

+31.18%

1-Day Range:

$26.50

$27.59

1-Week Range:

$26.15

$28.29

52-Week Range:

$12.91

$42.13

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name

Travere Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

888-969-7879

Address

3611 VALLEY CENTRE DR, SAN DIEGO

Employee

497

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

TVTX's Discussions on Twitter

Compare TVTX vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TVTX Travere Therapeutics Inc	27.56	2.47B	490.73M	-50.26M	-20.37M	-0.603
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-31-25	Reiterated	Citigroup	Buy
Jun-11-25	Reiterated	Citigroup	Buy
Jun-11-25	Resumed	H.C. Wainwright	Buy
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy
Nov-20-23	Initiated	Citigroup	Neutral
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform
Jul-21-23	Initiated	JP Morgan	Overweight
Jun-07-23	Resumed	Piper Sandler	Neutral
May-22-23	Initiated	TD Cowen	Outperform
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform
Dec-14-22	Initiated	Stifel	Hold
Dec-05-22	Initiated	Wells Fargo	Overweight
Sep-21-22	Initiated	Bryan Garnier	Sell
Jul-14-22	Resumed	Canaccord Genuity	Buy
Mar-31-22	Initiated	Piper Sandler	Overweight
Feb-28-22	Initiated	H.C. Wainwright	Buy
May-26-21	Downgrade	Wedbush	Outperform → Neutral

View All

Travere Therapeutics Inc Stock (TVTX) Latest News

Mar 25, 2026

JPMorgan Chase & Co. Has Lowered Expectations for Travere Therapeutics (NASDAQ:TVTX) Stock Price - MarketBeat

Mar 25, 2026

JP Morgan Lowers Price Target for TVTX to $41.00, Maintains Over - GuruFocus

Mar 25, 2026

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 25, 2026

Mar 23, 2026

Travere Therapeutics (TVTX) Gains Attention with Potential FDA A - GuruFocus

Mar 23, 2026

Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics - TipRanks

Mar 23, 2026

Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts - MSN

Mar 23, 2026

Mar 21, 2026

Travere Therapeutics (TVTX) reports 144% annual growth in Filspari sales for 2025 - MSN

Mar 21, 2026

Responsive Playbooks and the TVTX Inflection - Stock Traders Daily

Mar 21, 2026

Pullback Watch: Should value investors consider Travere Therapeutics Inc2026 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - baoquankhu1.vn

Mar 21, 2026